BeStock  
Stocks › Biotechnology › GLUE

Monte Rosa Therapeutics GLUE

US equityMarket cap rank #3343Biotechnology
$10.17 +$0.30 (+3.04%)
Pre-market · Oct 8, 7:50 am ET · After hours $10.00 -1.67%
Open$9.84
Prev close$9.87
Day range$9.68 – $10.75
Volume2.08M
Market cap$867.64M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$8.97M-61.3% YoY
Operating profit-$49.13M-215.9% YoY
Net profit-$43.40M-253.0% YoY
Diluted EPS-$0.43-186.7% YoY
Free cash flow-$48.84M-34.1% YoY
Operating cash flow-$44.11M

Revenue, last 8 quarters

$9.2MSep '24$60.6MDec '24$84.9MMar '25$23.2MJun '25$12.8MSep '25$2.8MDec '25$4.2MMar '26$9.0MJun '26

Net profit, last 8 quarters

$-23.9MSep '24$13.4MDec '24$46.9MMar '25$-12.3MJun '25$-27.1MSep '25$-46.1MDec '25$-44.5MMar '26$-43.4MJun '26

Diluted EPS by quarter

-0.29Sep '240.22Dec '240.57Mar '25-0.15Jun '25-0.33Sep '25-0.70Dec '25-0.45Mar '26-0.43Jun '26

Free cash flow by quarter

$-21.4MSep '24$128.7MDec '24$-47.1MMar '25$-36.4MJun '25$99.8MSep '25$-43.8MDec '25$-39.2MMar '26$-48.8MJun '26

Annual revenue

$0.0FY20$0.0FY21$0.0FY22$0.0FY23$75.6MFY24$123.7MFY25

Profitability & balance sheet

Operating margin-633.0%
Net margin-560.9%
Return on equity-42.7%
Return on assets-30.7%
Return on invested capital-42.8%
Current ratio10.58
Liabilities / assets29.5%
Cash & investments$621.10M
Total debt$33.36M
Net cash (debt)$587.75M

Income statement

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Revenue as Reported $8.97M $4.21M $123.67M $2.78M $12.77M
Total Operating Revenue $8.97M $4.21M $123.67M $2.78M $12.77M
Operating Expense $58.10M $54.24M $177.88M $52.50M $45.74M
Selling and Admin Expenses $10.13M $10.18M $36.38M $10.52M $9.07M
-General & Admin Expense $10.13M $10.18M $36.38M $10.52M $9.07M
Research & Development $47.96M $44.07M $141.50M $41.98M $36.68M
Operating Profit -$49.13M -$50.03M -$54.21M -$49.72M -$32.98M
Net Non-Operating Interest Income (Expense) $5.92M $5.59M $12.94M $3.69M $2.75M
Non-Operating Interest Income $5.92M $5.59M $12.94M $3.69M $2.75M
Other Income (Expense) $25,000.00 -$8,000.00 $1.54M -$50,000.00 -$29,000.00
Gain on Sale of Security $25,000.00 -$8,000.00 $1.48M -$50,000.00 -$29,000.00
Special Income (Charges) $0.00 $0.00 $59,000.00 $0.00 $0.00
-Gain on Sale of Property/Plant/Equipment $0.00 $0.00 $59,000.00 $0.00 $0.00
Pretax Profit -$43.19M -$44.45M -$39.72M -$46.08M -$30.26M
Tax $208,000.00 $52,000.00 -$1.10M $59,000.00 -$3.18M
Net Profit -$43.40M -$44.50M -$38.63M -$46.14M -$27.08M
Profit from Continuing Operations -$43.40M -$44.50M -$38.63M -$46.14M -$27.08M
Net Income to Parent Company -$43.40M -$44.50M -$38.63M -$46.14M -$27.08M
Net Income to Common Stockholders -$43.40M -$44.50M -$38.63M -$46.14M -$27.08M
Basic EPS -$0.43 -$0.45 -$0.46 -$0.70 -$0.33
Diluted EPS -$0.43 -$0.45 -$0.46 -$0.70 -$0.33

Balance sheet

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Assets $691.16M $736.43M $448.66M $448.66M $459.84M
Total Current Assets $631.41M $677.55M $393.19M $393.19M $401.82M
Cash and Cash Equivalents & Short-Term Investments $621.10M $666.22M $377.10M $377.10M $391.26M
-Cash and Cash Equivalents $90.10M $159.86M $129.88M $129.88M $208.34M
-Short Term Investments $531.00M $506.36M $247.22M $247.22M $182.92M
Receivables $4.92M $4.61M $11.60M $11.60M $4.97M
-Other Receivables $4.92M $4.61M $11.60M $11.60M $4.97M
Other Current Assets $5.38M $6.72M $4.48M $4.48M $5.59M
Total Non-Current Assets $59.76M $58.88M $55.47M $55.47M $58.02M
Net PPE $53.99M $53.10M $50.37M $50.37M $52.66M
-Gross PPE $85.54M $82.75M $77.99M $77.99M $78.19M
-Accumulated Depreciation -$31.55M -$29.64M -$27.61M -$27.61M -$25.52M
Other Non-Current Assets $5.77M $5.78M $5.10M $5.10M $5.36M
Total Liabilities $203.88M $214.51M $215.60M $215.60M $214.00M
Total Current Liabilities $59.66M $71.04M $64.21M $64.21M $61.44M
Payables $7.15M $7.90M $3.55M $3.55M $14.51M
-Accounts Payable $7.15M $7.90M $3.55M $3.55M $14.51M
Current Accrued Expenses $18.30M $19.31M $15.12M $15.12M $8.99M
Short-Term Debt and Capital Lease Obligation $4.63M $4.48M $4.40M $4.40M $4.24M
-Current Capital Lease Obligation $4.63M $4.48M $4.40M $4.40M $4.24M
Current Deferred Liabilities $22.10M $33.06M $29.57M $29.57M $24.79M
Other Current Liabilities $1.17M $1.24M $1.58M $1.58M $1.65M
Total Non-Current Liabilities $144.22M $143.48M $151.39M $151.39M $152.56M
Long Term Debt and Capital Lease Obligation $33.36M $34.58M $34.79M $34.79M $35.93M
-Long Term Capital Lease Obligation $33.36M $34.58M $34.79M $34.79M $35.93M
Non-Current Deferred Liabilities $105.62M $103.64M $111.33M $111.33M $111.89M
Employee Benefits $5.24M $5.26M $5.27M $5.27M $4.74M
Total Equity $487.28M $521.92M $233.06M $233.06M $245.84M
Stockholders' Equity $487.28M $521.92M $233.06M $233.06M $245.84M
Capital Stock $9,000.00 $8,000.00 $7,000.00 $7,000.00 $6,000.00
-Common Stock $9,000.00 $8,000.00 $7,000.00 $7,000.00 $6,000.00
-Preferred Stock $0.00 $0.00 – – $0.00
Additional Paid-In Capital $1.06B $1.05B $714.09M $714.09M $680.16M
Retained Earnings -$565.11M -$521.72M -$477.21M -$477.21M -$431.08M
Gains/Losses Not Affecting Retained Earnings -$5.17M -$4.75M -$3.83M -$3.83M -$3.25M
Convertible preferred securities – $0.00 $0.00 $0.00 –

Cash flow

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Operating Cash Flow -$44.11M -$37.37M -$22.80M -$43.01M $100.43M
Net cash flow from continuing operations -$44.11M -$37.37M -$22.80M -$43.01M $100.43M
Net Income from Continuing Operations -$43.40M -$44.50M -$38.63M -$46.14M -$27.08M
Depreciation & Depletion & Amortization $1.91M $2.03M $8.36M $2.09M $2.10M
Change in Working Capital -$7.63M $141,000.00 -$9.19M -$3.36M $121.52M
-Change in Receivables -$311,000.00 $6.99M -$11.43M -$6.64M -$2.60M
-Change in Prepaid Assets $1.34M -$2.92M $604,000.00 $1.38M $941,000.00
-Change in Payables and Accrued Expense $717,000.00 $665,000.00 -$5.86M -$1.88M $13.07M
-Change In Other Working Capital -$9.37M -$4.59M $7.49M $3.77M $110.10M
Net cash flow from investing -$28.86M -$261.00M -$101.83M -$65.07M $38.14M
Net Cash Flow from Continuing Investing Activities -$28.86M -$261.00M -$101.83M -$65.07M $38.14M
Net PPE Purchase and Sale -$4.72M -$1.87M -$4.70M -$767,000.00 -$651,000.00
Net Investment Purchase and Sale -$24.14M -$259.13M -$97.13M -$64.30M $38.79M
Financing Cash Flow $3.21M $328.34M $30.35M $29.62M $348,000.00
Net Cash Flow from Continuing Financing Activities $3.21M $328.34M $30.35M $29.62M $348,000.00
Net Common Stock Issuance $0.00 $324.30M $23.89M $23.89M $0.00
Proceeds from Stock Option Exercised $3.21M $4.52M $6.46M $5.73M $348,000.00
Net Other Financing Charges $0.00 -$487,000.00 – – –
Ending Cash Balance $95.04M $164.81M $134.84M $134.84M $213.29M
Net Change in Cash -$69.76M $29.97M -$94.28M -$78.46M $138.91M
Beginning Cash Balance $164.81M $134.84M $229.12M $213.29M $74.38M
Free Cash Flow -$48.84M -$39.24M -$27.50M -$43.78M $99.78M
Gain/Loss from Continuing Operations – – -$59,000.00 $0.00 $0.00

Discussion

No comments yet — be the first to weigh in on GLUE.

Leave a comment

Scroll to Top